Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Haltiwanger

Nurse Practitioner, Family Prosperity, SC Nurse Practitioner

NPI 1649432477 CMS profile 11248463

600 N Wheeler Ave, Prosperity, SC 29127

Open in the dashboard

General payments

$5,547

344 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Haltiwanger of Prosperity, SC is reported in the CMS Open Payments database as having received $5,547 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $984 55
2024 General $894 51
2023 General $1,314 85
2022 General $1,056 70
2021 General $1,299 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Haltiwanger
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Amanda Haltiwanger were reported at $984. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Amanda Haltiwanger Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,299 $124 $35–$379 $132
2022 $1,056 $141 $44–$430 $149
2023 $1,314 $154 $49–$476 $160
2024 $894 $165 $51–$504 $164
2025 $984 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $641 53 payments
  2. Pfizer Inc. $485 28 payments
  3. AstraZeneca Pharmaceuticals LP $475 24 payments
  4. Novo Nordisk Inc $429 30 payments
  5. GlaxoSmithKline, LLC. $360 26 payments
  6. Lilly USA, LLC $251 18 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $211 12 payments
  8. Amgen Inc. $189 12 payments
  9. Esperion Therapeutics, Inc. $183 10 payments
  10. Novartis Pharmaceuticals Corporation $162 9 payments
  11. Other $2,163 122 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,547 344 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $330 17 payments
  2. RYBELSUS $286 21 payments
  3. Ozempic $270 20 payments
  4. TRELEGY ELLIPTA $268 19 payments
  5. NURTEC ODT $247 14 payments
  6. UBRELVY $241 17 payments
  7. VRAYLAR $213 19 payments
  8. Kerendia $211 12 payments
  9. COMIRNATY $203 12 payments
  10. NEXLETOL $183 10 payments
  11. Other $5,344 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 125 drugs

Part D claims

6,203

Median for Nurse Practitioner: 389

Drug cost

$342,392

Median for Nurse Practitioner: $21,885

Branded share of claims

18.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 91 $100,549
Eliquis Apixaban Brand 37 $34,135
Mounjaro Tirzepatide Brand 14 $22,708
Jardiance Empagliflozin Brand 15 $18,385
Linzess Linaclotide Brand 17 $17,103
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $16,370
Xarelto Rivaroxaban Brand 25 $15,872
Farxiga Dapagliflozin Propanediol Brand 17 $14,199
Myrbetriq Mirabegron Brand 12 $13,894
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 11 $11,973

The 10 drugs with the highest cost, of 125 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $64
$64 11 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $40
$40 17 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $40
$40 20 —
RYBELSUS
  • Novo Nordisk Inc $35
$35 — —
Ozempic
  • Novo Nordisk Inc $35
$35 91 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record